These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1369672)

  • 21. The Discriminative Stimulus Properties of Hallucinogenic and Dissociative Anesthetic Drugs.
    Mori T; Suzuki T
    Curr Top Behav Neurosci; 2018; 39():141-152. PubMed ID: 27586539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A primate model for the study of hallucinogens.
    Schlemmer RF; Davis JM
    Pharmacol Biochem Behav; 1986 Feb; 24(2):381-92. PubMed ID: 3952128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Some effects of hallucinogenic morning-glory seeds on the behavior of rats.
    Gutherz K; Sperling SE
    Psychol Rep; 1966 Dec; 19(3):949-50. PubMed ID: 5981107
    [No Abstract]   [Full Text] [Related]  

  • 25. Screening hallucinogenic drugs II. Systematic study of two behavioral tests.
    Calil HM
    Psychopharmacology (Berl); 1978 Jan; 56(1):87-92. PubMed ID: 415331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designer drugs: a medicinal chemistry perspective.
    Carroll FI; Lewin AH; Mascarella SW; Seltzman HH; Reddy PA
    Ann N Y Acad Sci; 2012 Feb; 1248():18-38. PubMed ID: 22092008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alteration of a learned response of the squirrel monkey by hallucinogens.
    Uyeno ET
    Int J Neuropharmacol; 1969 May; 8(3):245-53. PubMed ID: 4978723
    [No Abstract]   [Full Text] [Related]  

  • 28. Psychedelic-inspired drug discovery using an engineered biosensor.
    Dong C; Ly C; Dunlap LE; Vargas MV; Sun J; Hwang IW; Azinfar A; Oh WC; Wetsel WC; Olson DE; Tian L
    Cell; 2021 May; 184(10):2779-2792.e18. PubMed ID: 33915107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intoxation with paramethoxymethamphetamine].
    Al-Samarraie MS; Vevelstad M; Nygaard IL; Bachs L; Mørland J
    Tidsskr Nor Laegeforen; 2013 May; 133(9):966-9. PubMed ID: 23652145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discriminative stimulus effects of hallucinogenic drugs: a possible relation to reinforcing and aversive effects.
    Mori T; Yoshizawa K; Shibasaki M; Suzuki T
    J Pharmacol Sci; 2012; 120(2):70-6. PubMed ID: 22986365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2C or not 2C: phenethylamine designer drug review.
    Dean BV; Stellpflug SJ; Burnett AM; Engebretsen KM
    J Med Toxicol; 2013 Jun; 9(2):172-8. PubMed ID: 23494844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hallucinogen Use Disorders.
    Hardaway R; Schweitzer J; Suzuki J
    Child Adolesc Psychiatr Clin N Am; 2016 Jul; 25(3):489-96. PubMed ID: 27338969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hallucinogens in Drug Discrimination.
    Baker LE
    Curr Top Behav Neurosci; 2018; 36():201-219. PubMed ID: 28484970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of specificity of an animal behavior model for hallucinogenic drug action.
    White FJ; Holohean AM; Appel JB
    Pharmacol Biochem Behav; 1981 Mar; 14(3):339-43. PubMed ID: 7232460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of tolerance to the hallucinogenic effects of DOM.
    Angrist B; Rotrosen J; Gershon S
    Psychopharmacologia; 1974 Apr; 36(3):203-7. PubMed ID: 4844244
    [No Abstract]   [Full Text] [Related]  

  • 36. Methodological issues of human experimental research with hallucinogens.
    Gouzoulis-Mayfrank E; Schneider F; Friedrich J; Spitzer M; Thelen B; Sass H
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():114-8. PubMed ID: 9754843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The psychopharmacology of hallucinogens.
    Abraham HD; Aldridge AM; Gogia P
    Neuropsychopharmacology; 1996 Apr; 14(4):285-98. PubMed ID: 8924196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models.
    Kyzar EJ; Kalueff AV
    Zebrafish; 2016 Oct; 13(5):379-90. PubMed ID: 27002655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early preclinical studies of discriminable sedative and hallucinogenic drug effects.
    Barry H; Appel JB
    Psychopharmacology (Berl); 2009 Apr; 203(2):193-201. PubMed ID: 18712362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models.
    Volgin AD; Yakovlev OA; Demin KA; Alekseeva PA; Kyzar EJ; Collins C; Nichols DE; Kalueff AV
    ACS Chem Neurosci; 2019 Jan; 10(1):143-154. PubMed ID: 30252437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.